Last reviewed · How we verify
ABP-671 plus allopurinol
At a glance
| Generic name | ABP-671 plus allopurinol |
|---|---|
| Sponsor | Atom Therapeutics Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Drug-Drug Interaction Study of ABP-671 in Gout Patients (PHASE1)
- Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout (PHASE2, PHASE3)
- Extension Study of ABP-671 in Participants With Gout (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP-671 plus allopurinol CI brief — competitive landscape report
- ABP-671 plus allopurinol updates RSS · CI watch RSS
- Atom Therapeutics Co., Ltd portfolio CI